White House sees decision on Moderna COVID shot for kids under 5 in next few weeks
Reuters
Published May 22, 2022 09:52AM ET
Updated May 22, 2022 10:20AM ET
WASHINGTON (Reuters) -White House COVID-19 response coordinator Dr. Ashish Jha said on Sunday he expects a U.S. Food and Drug Administration decision on authorizing Moderna (NASDAQ:MRNA)'s vaccine for children under age five within the next few weeks.
Moderna completed its application and FDA experts are looking closely at the data, Jha said on ABC's This Week with George Stephanopoulos, adding that the analysis is likely to be completed in the next few week and that a final decision would follow a meeting of the agency's expert advisers.
"So my hope is that it's going to be coming in the next few weeks," he said.
Jha said he expects more cases of monkeypox in the next few days, but that the United States is equipped to handle the virus because treatments and vaccines for it are available.
A large outbreak of monkeypox outside of Africa, where it is typically found, has caused concern among health experts. So far there have been 92 confirmed cases in areas not endemic to the virus - mostly in Europe - with one in the United States.
"I am confident we're going be able to keep our arms around it," Jha said, "but we're going to track it very closely and use the tools we have to make sure that we continue to prevent further spread and take care of the people who get infected."
Get The News You Want
Written By: Reuters
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.